

Regulated information

## Publication related to a transparency notification

(article 14, subparagraph 1 of the law of 2 May 2007 regarding the disclosure of important shareholdings in listed companies)

**Brussels, Belgium, 12 February 2018, 7.30 pm (CET)** – ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, today announces that it has received a transparency notification dated 9 February, 2018, the result of which is - following a capital increase completed on 25 January 2019 - that SA SFPI now has 8.87% of the Company's voting rights, and has thus decreased its stake below the 10% threshold.

The statement dated 9 February 2018 notably includes the following information:

- **Purpose of the notification**

Passive crossing of a threshold

- **Notification by**

A parent undertaking or a controlling person

- **Person subject to the notification requirement**

SFPI SA – Avenue Louise 32 b4, 1050 Brussels, Belgium  
Etat Belge – Rue de la Loi 12, 1000 Brussels, Belgium

- **Date of the transaction**

25 January 2018

- **Threshold crossed (%)**

Downward crossing of the 10% threshold.

- **Denominator**

A total of 15,262,544 voting rights

- **This notification is available on ASIT biotech's website, in the Documentation / Regulated information section:**

<https://www.asitbiotech.com/fr/investisseurs/documentation>

\*\*\*

## About ASIT biotech

ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech's product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at [www.asitbiotech.com](http://www.asitbiotech.com).

## Contacts

### Company

Thierry Legon, CEO  
ASIT biotech  
Tel.: +32 2 264 03 90  
[investors@asitbiotech.com](mailto:investors@asitbiotech.com)



### Media and Investor Relations - France

NewCap  
Dusan Oresansky / Pierre Laurent  
Tel.: +33 1 44 71 94 92  
[asitbiotech@newcap.eu](mailto:asitbiotech@newcap.eu)

### Media Relations - Belgium

Laure-Eve Monfort  
Tel.: +32 2 290 90 93  
[monfort@comfi.be](mailto:monfort@comfi.be)